Tale Of Two Adcomms: US FDA Handling Of Entresto Data May Have Helped Avoid Aducanumab’s Fate

 
• By Sue Sutter
  
night and day (shutterstock)
The advisory committee reviews of aducanumab and Entresto were as different as night and day. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers